The estimated Net Worth of Martin J Driscoll is at least $39.4 millier dollars as of 19 November 2020. Martin Driscoll owns over 10,000 units of Spring Bank Pharmaceuticals stock worth over $39,446 and over the last 9 years Martin sold SBPH stock worth over $0.
Sign up
Martin Driscoll SBPH stock SEC Form 4 insiders trading
Martin has made over 20 trades of the Spring Bank Pharmaceuticals stock since 2016, according to the Form 4 filled with the SEC. Most recently Martin exercised 10,000 units of SBPH stock worth $12,100 on 19 November 2020.
The largest trade Martin's ever made was buying 12,500 units of Spring Bank Pharmaceuticals stock on 11 May 2016 worth over $150,000. On average, Martin trades about 3,019 units every 64 days since 2016. As of 19 November 2020 Martin still owns at least 32,600 units of Spring Bank Pharmaceuticals stock.
You can see the complete history of Martin Driscoll stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Martin Driscoll's mailing address?
Martin's mailing address filed with the SEC is C/O SPRING BANK PHARMACEUTICALS, INC., 35 PARKWOOD DRIVE, SUITE 210, HOPKINTON, MA, 01748.
Insiders trading at Spring Bank Pharmaceuticals
Over the last 9 years, insiders at Spring Bank Pharmaceuticals have traded over $50,400 worth of Spring Bank Pharmaceuticals stock and bought 237,689 units worth $2,510,768 . The most active insiders traders include Todd C Brady, Scott Andrew Smith et Kurt M Eichler. On average, Spring Bank Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $8,517. The most recent stock trade was executed by Garrett Winslow on 19 November 2020, trading 6,250 units of SBPH stock currently worth $7,563.
What does Spring Bank Pharmaceuticals do?
Spring Bank Pharmaceuticals, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA.
What does Spring Bank Pharmaceuticals's logo look like?
Complete history of Martin Driscoll stock trades at Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals executives and stock owners
Spring Bank Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Kurt M Eichler,
Director -
Martin J Driscoll,
President and CEO -
David Arkowitz,
Director -
Christiana Bardon,
Director -
Timothy P Clackson,
Director -
Nezam H. Afdhal,
Chief Medical Officer -
Todd C Brady,
Director -
Jonathan Bates,
Director -
Scott Andrew Smith,
Director -
Jonathan Freve,
CFO & Treasurer -
Radhakrishnan P. Iyer,
Chief Scientific Officer -
Garrett Winslow,
General Counsel and Secretary -
Pamela M. Klein,
Director -
Lori Firmani,
VP of Finance and Treasurer